Kidney Disease News and Research

RSS

Phase 1 extension study results of Plexxikon's PLX4032 in metastatic melanoma patients encouraging

Plexxikon Inc. today announced encouraging clinical data from a Phase 1 extension study of PLX4032 (RG7204) in metastatic melanoma patients, which expand the results announced from the initial phase of the study. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors.

23 Sep 2009

Pros and cons of the estimated Glomerular Filtration Rate

As many as 26 million Americans live with chronic kidney disease (CKD) and according to the National Institutes of Health (NIH), at least 10.4 million (or 40%) don't even know they have it. Enter the estimated Glomerular Filtration Rate (eGFR), which has become the preferred method for identifying people with CKD.

23 Sep 2009

NIH, NephCure Foundation and University of Michigan support study of nephrotic syndrome

University of Michigan Health System researchers will lead a $10.25 million effort to study rare kidney diseases that cause kidney failure and the need for dialysis.

23 Sep 2009

$1.2 million grant to study centrosomes and cilia and their connections to human disease

If you don't know how a human cell is supposed to work, it's hard to offer a good explanation when the cell goes haywire -- as it does in cancer. That's why a Florida State University College of Medicine researcher has been awarded a $1.2 million grant to explore the role of centrosomes and cilia in cell division and development and their connections to human disease.

22 Sep 2009

Amgen announces results of Phase 3 head-to-head trial evaluating denosumab versus Zometa

Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa.

22 Sep 2009

Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy

Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.

22 Sep 2009

U.S. HHS orders for an additional 29 million doses of MedImmune's influenza vaccine

MedImmune announced today that the U.S. Department of Health and Human Services (HHS) has placed an order for an additional 29 million doses of its live attenuated influenza vaccine (LAIV) against the 2009 H1N1 influenza virus. This brings HHS orders to date to more than 40 million vaccine doses, with a total cumulative contract value of approximately $453 million.

22 Sep 2009

Many Australians at risk of having a heart attack are not receiving the best possible care: Study

The research suggests that GPs are still managing individual risk factors such as blood pressure and cholesterol in isolation of one another, and are not adopting recommendations to treat a patient's overall or absolute risk. Absolute risk management is based on the principle that the major risk factors for cardiovascular disease act together. By taking this approach treatment can be targeted to those most likely to benefit.

21 Sep 2009

The Transcatheter Cardiovascular Therapeutics 2009 to feature PLCs' RenalGuard System

PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate its RenalGuard System(TM) at Transcatheter Cardiovascular Therapeutics (TCT) 2009, sponsored by the Cardiovascular Research Foundation, September 21 - 25, 2009, in San Francisco, California. More than 11,000 clinicians and professionals are expected to attend this event.

21 Sep 2009

Optimized diabetes management with the CONTOUR(R) USB blood glucose meter

Bayer Diabetes Care today announced U.S. Food & Drug Administration clearance to market the CONTOUR(R) USB blood glucose meter. Bayer's CONTOUR USB meter is the first and only blood glucose monitor that plugs directly into a computer providing users with instant access to information that can help optimize diabetes management. The CONTOUR USB meter is integrated with Glucofacts(TM) DELUXE software for easy retrieval of data as well as longer-term tracking and analysis of blood glucose test results.

21 Sep 2009

Amgen announces results of Phase 3 trial in the treatment of bone metastases

Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3 trial evaluating denosumab administered subcutaneously versus Zometa(R) (zoledronic acid) administered as an intravenous infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. These results were presented today at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number: 20LBA).

21 Sep 2009

Program to promote patients’ overall health following kidney transplant surgery

Patient adherence after a kidney transplant, or faithfully following a prescribed medical regimen, is vital to a transplant recipient's health and the survival of their new organ.

19 Sep 2009

Texas attemps to offer access to quality dialysis care

Local officials, physicians and patients in need of local dialysis care expressed encouragement over what appears to be a thawing of a certification logjam of dialysis facilities across the state of Texas, though remain concerned over 38 which still remain idling to many for more than a year – to the detriment of local jobs and patients in dire need of better access to quality dialysis care.

18 Sep 2009

Recipients of 2009 Norman S. Coplon Extramural Grants

Satellite Healthcare, one of the nation's first and leading providers of kidney dialysis services and a major sponsor of nephrology research, today announced the recipients of the 2009 Norman S. Coplon Extramural Grant Program.

18 Sep 2009

'Pathway to a Cure' walk event in California

Satellite Healthcare, one of the nation's first and leading providers of kidney dialysis services and a major sponsor of nephrology research, today announced their sponsorship of The Polycystic Kidney Disease Foundation's "Pathway to a Cure" walk event in California's capital of Sacramento.

18 Sep 2009

Researchers to focus on abnormal fetal growth and chronic kidney disease

The National Institutes of Health (NIH) has awarded Albert Einstein College of Medicine of Yeshiva University two grants totaling $3.5 million to study epigenetic changes - chemical modifications of genes caused by stress, diet or other environmental influences - and how they contribute to human diseases and biological processes.

18 Sep 2009

NIDDK awards $1.2 million grant to Bolder BioTechnology for long-acting EPO analog program

Bolder BioTechnology, Inc. announced today that it has been awarded a $1.2 million Phase II Small Business Innovation Research (SBIR) grant, entitled "Long-Acting EPO Analog for Treating Anemia Associated with Chronic Kidney Disease," from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of The National Institutes of Health (NIH). Receipt of the entire grant award is contingent upon the achievement of certain research milestones.

18 Sep 2009

Preventive treatment extension after kidney transplantation reduces the risk of CMV disease

For kidney transplant recipients, infection with a virus called cytomegalovirus (CMV) may lead to devastating complications. New research suggests that extending the period of preventive treatment after kidney transplantation can reduce the risk of CMV disease, according to an upcoming report in the Journal of the American Society of Nephrology (JASN).

18 Sep 2009

NIH to fund grants for epigenetic research

The National Institutes of Health announced today that it will fund 22 grants on genome-wide studies of how epigenetic changes -- chemical modifications to genes that result from diet, aging, stress, or environmental exposures -- define and contribute to specific human diseases and biological processes.

17 Sep 2009

Amgen to present its four Phase 3 clinical trial results

Amgen today announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany.

16 Sep 2009

Kidney Disease News and Research

Phase 1 extension study results of Plexxikon's PLX4032 in metastatic melanoma patients encouraging

Pros and cons of the estimated Glomerular Filtration Rate

NIH, NephCure Foundation and University of Michigan support study of nephrotic syndrome

$1.2 million grant to study centrosomes and cilia and their connections to human disease

Amgen announces results of Phase 3 head-to-head trial evaluating denosumab versus Zometa

Amgen announces Phase 3 results evaluating Vectibix in combination with FOLFIRI chemotherapy

U.S. HHS orders for an additional 29 million doses of MedImmune's influenza vaccine

Many Australians at risk of having a heart attack are not receiving the best possible care: Study

The Transcatheter Cardiovascular Therapeutics 2009 to feature PLCs' RenalGuard System

Optimized diabetes management with the CONTOUR(R) USB blood glucose meter

Amgen announces results of Phase 3 trial in the treatment of bone metastases

Program to promote patients’ overall health following kidney transplant surgery

Texas attemps to offer access to quality dialysis care

Recipients of 2009 Norman S. Coplon Extramural Grants

'Pathway to a Cure' walk event in California

Researchers to focus on abnormal fetal growth and chronic kidney disease

NIDDK awards $1.2 million grant to Bolder BioTechnology for long-acting EPO analog program

Preventive treatment extension after kidney transplantation reduces the risk of CMV disease

NIH to fund grants for epigenetic research

Amgen to present its four Phase 3 clinical trial results

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News